P. Sabbatini

发表

Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

Donavan T. Cheng, Alexander V Penson, Benjamin E. Gross, 2017, Nature Medicine.

OncoKB: A Precision Oncology Knowledge Base.

Moriah H Nissan, B. Taylor, N. Schultz, 2017, JCO precision oncology.

Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.

S. Soignet, P. Sabbatini, M. Demario, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Deborah Schrag, Allison Barz, Ethan Basch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient online self-reporting of toxicity symptoms during chemotherapy.

Nandita Mitra, David Artz, Deborah Schrag, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epithelial ovarian cancer.

Ardeshir Hakam, Paul Sabbatini, P. Grigsby, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Epithelial Ovarian CancerPractice Guidelines in Oncology

P. Grigsby, R. Burger, P. Sabbatini, 2011 .

Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A. Iasonos, P. Sabbatini, K. Odunsi, 2006, Clinical Cancer Research.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

J. Berek, P. Sabbatini, T. Pintér, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

R. Burger, M. Morgan, P. Sabbatini, 2019, Gynecologic oncology.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer

A. Iasonos, P. Sabbatini, D. Hyman, 2018, International Journal of Gynecologic Cancer.

Ovarian cancer, version 3.2012.

R. Burger, M. Dwyer, P. Sabbatini, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Consolidation strategies in ovarian cancer: observations for future clinical trials.

A. Iasonos, P. Sabbatini, C. Aghajanian, 2010, Gynecologic oncology.

"This issue of Therapy reviews ongoing studies on numerous fronts that have the potential to further improve outcomes related to the prevention, diagnosis and treatment of patients with ovarian cancer. "

P. Sabbatini, J. Pfisterer, 2010 .

CON: Patients with Recurrent Ovarian Carcinoma Should Not Be Treated with Antiangiogenic Agents in Combination with Chemotherapy

P. Sabbatini, 2009 .

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

E. Venkatraman, M. Gore, A. Iasonos, 2007, Gynecologic oncology.

Cancer- and chemotherapy-induced anemia.

M. Millenson, R. Vij, C. Cleeland, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.

E. Venkatraman, D. Chi, P. Sabbatini, 2001, Gynecologic oncology.

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2007, Clinical Cancer Research.

Early CA‐125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy

H. Thaler, A. Iasonos, P. Sabbatini, 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.

Suzanne F. Jones, P. Sabbatini, H. Burris, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.

M. Kris, C. Hudis, E. Basch, 2017 .

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

P. Sabbatini, J. Dupont, C. Aghajanian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

D. Levine, R. Barakat, W. Jarnagin, 2004, Gynecologic oncology.

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

P. Sabbatini, A. Hummer, J. Dupont, 2003, Gynecologic oncology.

Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation

C. Begg, Gregory Riely, P. Sabbatini, 2022, JAMA network open.

Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.

P. Sabbatini, T. Traina, J. Dupont, 2004, Gynecologic oncology.

p53, epidermal growth factor, and platelet‐derived growth factor in uterine leiomyosarcoma and leiomyomas

A. Olshen, D. Chi, P. Sabbatini, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology

P. Sabbatini, E. Ratner, L. Havrilesky, 2016 .

Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination

A. Iasonos, P. Sabbatini, C. Aghajanian, 2022, Cancer Immunology, Immunotherapy.

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

A. Iasonos, P. Sabbatini, L. Old, 2008, Clinical Cancer Research.

Impact of Prophylactic Conversion to an Extended Infusion Schedule to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients during Carboplatin Retreatment

A. Iasonos, P. Sabbatini, C. Aghajanian, 2015 .

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.

A. Iasonos, P. Sabbatini, C. Aghajanian, 2010, Gynecologic oncology.

Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?

E. Venkatraman, P. Sabbatini, J. Dupont, 2005, International Journal of Gynecologic Cancer.

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.

E. Venkatraman, P. Sabbatini, A. Hummer, 2003, Gynecologic oncology.

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.

D. Chi, P. Sabbatini, C. Aghajanian, 2001, Gynecologic oncology.

Salvage therapy for ovarian cancer.

P. Sabbatini, D. Spriggs, 1998, Oncology.

New agents for the treatment of ovarian cancer: the next generation

P. Sabbatini, J. Dupont, C. Aghajanian, 2005, International Journal of Gynecologic Cancer.

Engaging Community-Based Cancer Physicians: Experience of the Memorial Sloan Kettering Cancer Center Cancer Alliance.

D. Pfister, P. Sabbatini, D. Korenstein, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Identifying Clinical Improvement in Consolidation Single-Arm Phase 2 Trials in Patients With Ovarian Cancer in Second or Greater Clinical Remission

H. Thaler, A. Iasonos, P. Sabbatini, 2012, International Journal of Gynecologic Cancer.

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

R. Barakat, D. Chi, A. Iasonos, 2008, Gynecologic oncology.

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

R. Barakat, D. Chi, P. Sabbatini, 2006, Gynecologic oncology.

Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer

E. Venkatraman, D. Chi, P. Sabbatini, 2004, Clinical Cancer Research.

Immunization of ovarian cancer patients with a synthetic Lewisy‐protein conjugate vaccine: A phase 1 trial

M. Peyton, S. Soignet, P. Sabbatini, 2000, International journal of cancer.

Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.

E. Venkatraman, R. Barakat, P. Sabbatini, 1999, Gynecologic oncology.

Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma.

R. Barakat, P. Sabbatini, S. Makhija, 1999, Current opinion in obstetrics & gynecology.

Epothilones: better or more of the same?

P. Sabbatini, D. Spriggs, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

P. Sabbatini, D. Hyman, J. Dupont, 2012, Investigational new drugs.

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.

P. Sabbatini, R. Buller, A. Melemed, 2003, Gynecologic oncology.

A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer

P. Sabbatini, C. Aghajanian, M. Orlando, 2008, Clinical Cancer Research.

Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in SolidTumorMalignancies orAdvanced Epithelial Ovarian Cancer

P. Sabbatini, C. Aghajanian, M. Orlando, 2008 .

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

D. Chi, A. Iasonos, P. Sabbatini, 2021, Gynecologic oncology.

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer

P. Sabbatini, J. Dupont, C. Aghajanian, 2005 .

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

P. Sabbatini, L. Old, C. Aghajanian, 2012, Clinical Cancer Research.

Cancer- and treatment-related anemia: Clinical Practice Guidelines in Oncology

M. Millenson, G. Demetri, C. Cleeland, 2005 .

NCCN Cancer- and Treatment-Related Anemia Panel Members

P. Sabbatini, V. Mock, 2007 .

Cancer- and treatment-related anemia.

M. Millenson, G. Demetri, C. Cleeland, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125

R. Kreienberg, P. Sabbatini, J. Huober, 2004, Clinical Cancer Research.

Reply to the Letter to the Editor from Schultes et al

P. Sabbatini, K. Odunsi, 2007, Clinical Cancer Research.

A. Abernethy, F. M. Stewart, P. Hinds, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade

A. Snyder, A. Iasonos, P. Sabbatini, 2018, Gynecologic oncology.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

P. Sabbatini, E. Ratner, L. Havrilesky, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Supplemental online content for : NCCN Guidelines ® Insights : Ovarian Cancer , Version 1 . 2019

D. Matei, A. Berchuck, J. Berek, 2019 .

Authors' reply to Drs. Khattak and Martin

W. Shi, H. Thaler, P. Sabbatini, 2012 .

Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.

D. Levine, R. Barakat, D. Chi, 2009, Gynecologic oncology.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

H. Thaler, A. Iasonos, P. Sabbatini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is There a Role for Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer Off-Protocol?

P. Sabbatini, J. Meisel, 2012 .

Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma.

R. Barakat, L. Ben-Porat, P. Sabbatini, 2005, Gynecologic oncology.

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

P. Sabbatini, C. Aghajanian, D. Spriggs, 2002, Gynecologic oncology.

A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.

A. Iasonos, P. Sabbatini, C. Aghajanian, 2008, European journal of gynaecological oncology.

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC).

G. Coukos, P. Sabbatini, P. Schwarzenberger, 2018, Annals of Oncology.

Anemia clinical practice guidelines in oncology.

P. Sabbatini, 2003, The Journal of the National Comprehensive Cancer Network.

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

P. Sabbatini, R. Coleman, T. Herzog, 2015 .

Phase I study of MORAb-003, a humanized anti-folate receptor-alpha monoclonal antibody, in platinum resistant ovarian cancer.

P. Sabbatini, J. Dupont, C. Aghajanian, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Donavan T. Cheng, Alexander V Penson, Benjamin E. Gross, 2017, Nature Medicine.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

F. Dao, D. Chi, P. Sabbatini, 2012, Gynecologic oncology.

Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213.

P. Sabbatini, R. Coleman, T. Herzog, 2016 .

A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2007 .

Ovarian cancer, version 2.2013.

R. Burger, M. Dwyer, P. Sabbatini, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Ovarian cancer. Clinical practice guidelines in oncology.

P. Grigsby, J. Lancaster, R. Ozols, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Ovarian cancer. Clinical practice guidelines in oncology.

J. Lancaster, R. Ozols, P. Sabbatini, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Endometrial stromal sarcoma: objective response to letrozole.

L. Schwartz, P. Sabbatini, C. Aghajanian, 2001, Gynecologic oncology.

CASE REPORT Endometrial Stromal Sarcoma: Objective Response to Letrozole

L. Schwartz, P. Sabbatini, C. Aghajanian, 2001 .

OncoKB: Annotation of the oncogenic effect and treatment implications of somatic mutations in cancer.

N. Schultz, M. Ladanyi, S. Chandarlapaty, 2016 .

NCCN Practice Guidelines for Cancer-Related Fatigue.

P. Hinds, C. Cleeland, D. Cella, 2000, Oncology.

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

P. Sabbatini, C. Aghajanian, D. Spriggs, 2009, Gynecologic oncology.

Implementation of disease management guidelines in patients with advanced ovarian cancer.

P. Sabbatini, D. Spriggs, M. Hensley, 1999, Seminars in Oncology.

REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy

P. Sabbatini, K. Odunsi, 2007, American journal of reproductive immunology.

Immunologic approaches to ovarian cancer treatment.

P. Sabbatini, K. Odunsi, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

A. Olshen, R. Barakat, P. Sabbatini, 2004, Cancer.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

E. Venkatraman, R. Barakat, R. Maki, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial

P. Sabbatini, D. Spriggs, S. Gnjatic, 2013, Cancer Immunology Research.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

T. Rebbeck, R. Eeles, C. Hudis, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

S. Soignet, P. Elliott, P. Sabbatini, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Consolidation Therapy in Ovarian Cancer: A Clinical Update

P. Sabbatini, 2009, International Journal of Gynecologic Cancer.

OncoTree: A Cancer Classification System for Precision Oncology.

Benjamin E. Gross, Stuart M. Gardos, N. Schultz, 2021, JCO clinical cancer informatics.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

B. Taylor, M. Ladanyi, M. Berger, 2018, Clinical Cancer Research.

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

B. Karlan, P. Sabbatini, L. Fehrenbacher, 2012, Clinical Cancer Research.

Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.

C. Sima, D. Levine, R. Barakat, 2009, Gynecologic oncology.

Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.

D. Levine, R. Barakat, D. Chi, 2008, American journal of obstetrics and gynecology.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Alexia Iasonos, Paul Sabbatini, R. Barakat, 2007, Gynecologic oncology.

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

P. Sabbatini, C. Aghajanian, D. Spriggs, 2008, Gynecologic oncology.

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study

R. Barakat, P. Sabbatini, J. Dupont, 2006, International Journal of Gynecologic Cancer.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Danielle M. Enserro, Jae-Weon Kim, P. Sabbatini, 2019, The New England journal of medicine.

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

A. Iasonos, H. Won, P. Sabbatini, 2019, Cancer.

Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary.

R. Barakat, D. Chi, P. Sabbatini, 2006, Gynecologic oncology.

Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines

R. Burger, M. Dwyer, P. Sabbatini, 2013 .

Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

J. Berek, P. Sabbatini, J. Pfisterer, 2011, Immunotherapy.

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

E. Venkatraman, D. Chi, P. Sabbatini, 2007, Investigational New Drugs.

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

S. Larson, H. Scher, Zuo-Feng Zhang, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

K. Offit, R. Barakat, P. Sabbatini, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.

H. Hricak, O. Akin, R. Barakat, 2012, AJR. American journal of roentgenology.

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2021, Journal for ImmunoTherapy of Cancer.

Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.

A. Iasonos, P. Sabbatini, M. Callahan, 2020, Gynecologic oncology.

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.

A. Iasonos, P. Sabbatini, C. Aghajanian, 2020, Gynecologic oncology.

A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer

E. Venkatraman, D. Chi, P. Sabbatini, 2006, International Journal of Gynecologic Cancer.

Eribulin mesylate (halichondrin B analog E7389) in platinum‐resistant and platinum‐sensitive ovarian cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2012, Cancer.

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

D. Levine, R. Barakat, H. Thaler, 2007, Gynecologic oncology.

Early detection and prognosis of ovarian cancer using serum YKL-40.

H. Thaler, E. Holland, P. Sabbatini, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

E. Venkatraman, P. Sabbatini, A. Hummer, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission

D. Levine, A. Iasonos, P. Sabbatini, 2007, Cancer.

Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumor malignancies

S. Soignet, P. Sabbatini, L. Krug, 2001 .

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.

R. Barakat, D. Chi, P. Sabbatini, 2010, Gynecologic oncology.

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

J. Raizer, P. Sabbatini, J. Dupont, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A. Iasonos, P. Sabbatini, C. Aghajanian, 2015, International Journal of Gynecologic Cancer.

Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer

D. Chi, P. Sabbatini, A. Leiser, 2005, International Journal of Gynecologic Cancer.

Ovarian cancer in 2010

P. Sabbatini, J. Pfisterer, 2010 .

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

A. Iasonos, P. Sabbatini, D. Spriggs, 2016, Cancers.

Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies.

P. Sabbatini, J. Dupont, C. Aghajanian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission

P. Sabbatini, C. Aghajanian, S. Gnjatic, 2023, Cancers.

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.

P. Sabbatini, C. Muller, K. Behbakht, 2019, Gynecologic oncology.

Consolidation for ovarian cancer in remission.

P. Sabbatini, D. Spriggs, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Danielle M. Enserro, A. Secord, P. Sabbatini, 2018 .

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

L. Schwartz, S. Gettinger, J. Cedarbaum, 2009, Clinical Cancer Research.

Advanced ovarian cancer

D. Chi, P. Sabbatini, 2000, Current treatment options in oncology.

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.

E. Venkatraman, D. Correa, H. Thaler, 2006, Gynecologic oncology.

Intraperitoneal chemotherapy in older women with epithelial ovarian cancer

W. Shi, H. Thaler, P. Sabbatini, 2012 .

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study

S. Larson, P. Sabbatini, L. Old, 2010, Clinical Cancer Research.

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

Donavan T. Cheng, Marc Ladanyi, David M Hyman, 2015, Drug discovery today.

Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report.

W. Jarnagin, D. Chi, P. Sabbatini, 2002, Gynecologic oncology.

Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second‐look assessment

D. Levine, R. Barakat, P. Sabbatini, 2008, Cancer.

CASE REPORT Major Hepatectomy at Interval Debulking for Stage IV Ovarian Carcinoma: A Case Report

W. Jarnagin, D. Chi, P. Sabbatini, 2002 .

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

E. Venkatraman, S. Soignet, R. Barakat, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complications associated with intraperitoneal chemotherapy catheters.

R. Barakat, P. Sabbatini, D. Spriggs, 2001, Gynecologic oncology.

Predictors of early treatment discontinuation in ovarian cancer patients on checkpoint blockade immunotherapy

A. Iasonos, P. Sabbatini, C. Aghajanian, 2018, Gynecologic Oncology.

Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.

E. Venkatraman, R. Barakat, P. Sabbatini, 2000, Gynecologic Oncology.

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study

P. Sabbatini, A. Lesokhin, O. Landgren, 2023, EClinicalMedicine.

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

A. Secord, P. Sabbatini, D. O’Malley, 2008, Gynecologic oncology.

Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer.

C. Begg, Gregory Riely, P. Sabbatini, 2022, JAMA oncology.

New agents and new formulations for the treatment of ovarian cancer.

P. Sabbatini, 2005, Clinical advances in hematology & oncology : H&O.

Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis

A. Iasonos, P. Sabbatini, C. Aghajanian, 2022, Gynecologic oncology reports.

A phase I study of pemetrexed (P) plus gemcitabine (G) in relapsed ovarian cancer (OC): Dosing results and evidence of activity.

P. Sabbatini, J. Dupont, C. Aghajanian, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strategies for optimizing hemoglobin response in cancer patients: focus on new epoetin alfa dosing regimens

P. Sabbatini, 2004 .

Digitalizing the Clinical Research Informed Consent Process: Assessing the Participant Experience in Comparison With Traditional Paper-Based Methods

G. Kuperman, A. Iasonos, P. Sabbatini, 2022, JCO oncology practice.

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.

R. Wenham, A. Secord, P. Sabbatini, 2023, Gynecologic oncology.

Treating cancer symptoms improves quality of life. Part I: treatment of anaemia and fatigue

P. Sabbatini, 2000, International Journal of Pharmaceutical Medicine.

Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.

L. Ben-Porat, D. Chi, P. Sabbatini, 2004, Gynecologic oncology.

Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemo

P. Sabbatini, Byoung-Gie Kim, R. Coleman, 2015 .

Electronic research consents for complex early-phase I-II clinical trials integrated with telemedicine visits compared with in-person encounters.

G. Kuperman, P. Sabbatini, A. Lipitz-Snyderman, 2022, Journal of Clinical Oncology.

Fast, light, and scalable: harnessing data-mined line annotations for automated tumor segmentation on brain MRI

Benjamin E. Gross, Alice M. L. Santilli, Jianjiong Gao, 2023, European Radiology.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Donavan T. Cheng, Benjamin E. Gross, Michael H. Eubank, 2017, Nature Network Boston.

Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.

J. Berek, P. Sabbatini, T. Pintér, 2010 .

Abagovomab for ovarian cancer

J. Berek, P. Sabbatini, P. Harter, 2011, Expert opinion on biological therapy.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) trial.

J. Berek, P. Sabbatini, T. Pintér, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) tria

J. Berek, P. Sabbatini, T. Pintér, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

Gregory Riely, M. Hellmann, P. Sabbatini, 2021, Cancer Cell.

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.

N. Schultz, K. Offit, Ritika Kundra, 2023, Gynecologic oncology.

Epithelial ovarian cancer.

P. Sabbatini, L. Havrilesky, A. Hakam, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

D. Matei, A. Berchuck, J. Berek, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission.

P. Sabbatini, L. Old, S. Gnjatic, 2010 .

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

N. Schultz, M. Ladanyi, A. Drilon, 2023, Cancer discovery.

Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).

M. Fischer, P. Sabbatini, F. Cattaruzza, 2016 .

Effect of metformin on recurrence-free survival and overall survival in diabetic patients affected by advanced ovarian cancer.

J. Berek, P. Sabbatini, M. Binaschi, 2013 .